LD-2 disclosure · 2nd Quarter - Report

EMD MILLIPORE CORPORATION

2nd Quarter (Apr 1 - June 30) · 2026Posted Jul 20, 2026Filing document ↗LDA record ↗

Expenses$100Kself-filed spend

Client

Name: EMD MILLIPORE CORPORATION
Description: Manufacturing of preparation, separation, filtration and monitoring life sciences tools.
Location: District of Columbia · United States of America

2 issues

Tariff (miscellaneous tariff bills)
Section 301 Tariffs - Discussions related to the impact of Reciprocal Tariffs on U.S. biomanufacturing Section 232 Tariffs - Discussions related to the impact of Pharmaceutical Tariffs on U.S. biomanufacturing
LobbyistsANDREW TANTILLO
TargetedHOUSE OF REPRESENTATIVES · U.S. Trade Representative (USTR) · Commerce, Dept of (DOC)
Manufacturing
General discussions related to federal procurement policy
LobbyistsANDREW TANTILLO
TargetedOffice of Management & Budget (OMB)

LD-2 disclosure · 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) · 2026Posted Jul 20, 2026Filing document ↗LDA record ↗

Expenses$100Kself-filed spend

Name: EMD MILLIPORE CORPORATION
Description: Manufacturing of preparation, separation, filtration and monitoring life sciences tools.
Location: District of Columbia · United States of America

2 issues

Tariff (miscellaneous tariff bills)
Section 301 Tariffs - Discussions related to the impact of Reciprocal Tariffs on U.S. biomanufacturing Section 232 Tariffs - Discussions related to the impact of Pharmaceutical Tariffs on U.S. biomanufacturing
LobbyistsANDREW TANTILLO
TargetedHOUSE OF REPRESENTATIVES · U.S. Trade Representative (USTR) · Commerce, Dept of (DOC)
Manufacturing
General discussions related to federal procurement policy
LobbyistsANDREW TANTILLO
TargetedOffice of Management & Budget (OMB)